Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice

Cardiovascular Research

Volumn 85, Issue 3, 2010, Pages 622-630

  Habets, Kim L L ^a   Van Puijvelde, Gijs H M ^a   Van Duivenvoorde, Leonie M ^b   Van Wanrooij, Eva J A ^a   De Vos, Paula ^a   Tervaert, Jan Willem Cohen ^c   Van Berkel, Theo J C ^a   Toes, Rene E M ^b   Kuiper, Johan ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Antigen presenting cells; Atherosclerosis; Dendritic cells; Immunotherapy

Indexed keywords

DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; BONE MARROW CELL; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FOAM CELL; GENETIC TRANSFECTION; HUMORAL IMMUNITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE; VACCINATION;

ANIMALS; ATHEROSCLEROSIS; BODY WEIGHT; CHOLESTEROL; CYTOKINES; DENDRITIC CELLS; IMMUNOGLOBULIN G; LIPOPROTEINS, LDL; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, LDL; VACCINATION;

EID: 74249123382     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp338     Document Type: Article

References (46)

1. Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 2003;10:63-71.
2. Goldschmidt-Clermont PJ, Creager MA, Losordo DW, Lam GK, Wassef M, Dzau VJ. Atherosclerosis 2005: recent discoveries and novel hypotheses. Circulation 2005;112:3348-3353.
3. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135-1143.
4. Lusis AJ. Atherosclerosis. Nature 2000;407:233-241.
5. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:1876-1890.
6. Hansson GK. Cell-mediated immunity in atherosclerosis. Curr Opin Lipidol 1997;8: 301-311
7. Hendrix MG, Dormans PH, Kitslaar P, Bosman F, Bruggeman CA. The presence of cytomegalovirus nucleic acids in arterial walls of atherosclerotic and nonathero-sclerotic patients. Am J Pathol 1989;134:1151-1157.
8. Wick G, Kleindienst R, Schett G, Amberger A, Xu Q. Role of heat shock protein 65/60 in the pathogenesis of atherosclerosis. Int Arch Allergy Immunol 1995;107: 130-131.
9. Ameli S, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yano J, Cercek B et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996;16: 1074-1079.
10. Fredrikson GN, Soderberg I, Lindholm M, Dimayuga P, Chyu KY, Shah PK et al. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 2003;23:879-884.
11. Freigang S, Horkko S, Miller E, Witztum JL, Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 1998;18:1972-1982.
12. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ et al. Immunobi-ology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
13. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245-3287.
14. Sallusto F, Lanzavecchia A. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev 2000;177: 134-140.
15. Alderman CJ, Bunyard PR, Chain BM, Foreman JC, Leake DS, Katz DR. Effects of oxidised low density lipoprotein on dendritic cells: a possible immunoregulatory component of the atherogenic micro-environment? Cardiovasc Res 2002;55: 806-819.
16. Perrin-Cocon L, Coutant F, Agaugue S, Deforges S, Andre P, Lotteau V. Oxidized low-density lipoprotein promotes mature dendritic cell transition from differentiating monocyte. J Immunol 2001;167:3785-3791.
17. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-480.
18. Dubsky P, Ueno H, Piqueras B, Connolly J, Banchereau J, Palucka AK. Human dendritic cell subsets for vaccination. J Clin Immunol 2005;25:551-572.
19. Redgrave TG, Roberts DC, West CE. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem 1975;65:42-49.
20. Van Berkel TJ, De Rijke YB, Kruijt JK. Different fate in vivo of oxidatively modified low density lipoprotein and acetylated low density lipoprotein in rats. Recognition by various scavenger receptors on Kupffer and endothelial liver cells. J Biol Chem 1991;266:2282-2289.
21. von der Thusen JH, van Berkel TJ, Biessen EA. Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation 2001;103:1164-1170.
22. van Puijvelde GH, Hauer AD, de Vos P, van den Heuvel R, van Herwijnen MJ, van der Zee R et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 2006;114:1968-1976.
23. Bobryshev YV. Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur Heart J 2005;26:1700-1704.
24. Bobryshev YV, Lord RS. Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of vascular dendritic cells in athero-resistant and athero-prone areas of the normal aorta. Arch Histol Cytol 1995;58:307-322.
25. Llodra J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci USA 2004;101:11779-11784.
26. Bobryshev YV, Lord RS. Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Car-diovasc Res 1998;37:799-810.
27. Angeli V, Llodra J, Rong JX, Satoh K, Ishii S, Shimizu T et al. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 2004;21:561-574.
28. Schimmelpfennig CH, Schulz S, Arber C, Baker J, Tarner I, McBride J et al. Ex vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantation. Am J Pathol 2005;167: 1321-1331.
29. Bluml S, Kirchberger S, Bochkov VN, Kronke G, Stuhlmeier K, Majdic O et al. Oxidized phospholipids negatively regulate dendritic cell maturation induced by TLRs and CD40. J Immunol 2005;175:501-508.
30. Packard RR, Maganto-Garcia E, Gotsman I, Tabas I, Libby P, Lichtman AH. CD11c(+) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. Circ Res 2008;103:965-973.
31. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995;92:821-825.
32. Fredrikson GN, Andersson L, Soderberg I, Dimayuga P, Chyu KY, Shah PK et al. Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression. Auto-immunity 2005;38:171-179.
33. VanderLaan PA, Reardon CA, Getz GS. Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators. Arterioscler Thromb Vasc Biol 2004;24:12-22.
34. van Puijvelde GH, van Es T, van Wanrooij EJ, Habets KL, de Vos P, van der Zee R et al. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27: 2677-2683.
35. Dekker RJ, van Thienen JV, Rohlena J, de Jager SC, Elderkamp YW, Seppen J et al. Endothelial KLF2 links local arterial shear stress levels to the expression of vascular tone-regulating genes. Am J Pathol 2005;167:609-618.
36. Menges M, Rossner S, Voigtlander C, Schindler H, Kukutsch NA, Bogdan C et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med 2002; 195:15-21.
37. van Duivenvoorde LM, Louis-Plence P, Apparailly F, van der Voort EI, Huizinga TW, Jorgensen C et al. Antigen-specific immunomodulation of collagen-induced arthritis with tumor necrosis factor-stimulated dendritic cells. Arthritis Rheum 2004;50:3354-3364.
38. Farkas A, Conrad C, Tonel G, Borbenyi Z, Kemeny L, Dobozy A et al. Current state and perspectives of dendritic cell vaccination in cancer immunotherapy. Skin Pharmacol Physiol 2006;19:124-131.
39. Garcia F, Lejeune M, Climent N, Gil C, Alcami J, Morente V et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005;191:1680-1685.
40. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004;10:1359-1365.
41. Hauer AD, Uyttenhove C, de Vos P, Stroobant V, Renauld JC, van Berkel TJ et al. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 2005;112:1054-1062.
42. Shaw PX, Horkko S, Tsimikas S, Chang MK, Palinski W, Silverman GJ et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 2001;21:1333-1339.
43. Caligiuri G, Khallou-Laschet J, Vandaele M, Gaston AT, Delignat S, Mandet C et al. Phosphorylcholine-targeting immunization reduces atherosclerosis. J Am Coll Cardiol 2007;50:540-546.
44. Zhou X, Caligiuri G, Hamsten A, Lefvert AK, Hansson GK. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:108-114.
45. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484-486.
46. Schiopu A, Frendeus B, Jansson B, Soderberg I, Ljungcrantz I, Araya Z et al. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(2/2)/low-density lipoprotein receptor(2/2) mice. J Am Coll Cardiol 2007;50:2313-2318.